Market Spotlight: Opioid-Induced Constipation


Report
27 Pages
February 2021
Region: Global
Citeline
ID: 4533472

This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and epidemiology data, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The approved drugs in the opioid-induced constipation (OIC) space predominantly target opioid receptors, with the exception of Amitiza, a type-2 chloride channel activator. All of the marketed drugs are administered via the oral route, with one product also being available in a subcutaneous formulation.
There are only two industry-sponsored drugs in active clinical development for OIC, with one drug each in Phase II and Phase III. Therapies in active clinical development for OIC target opioid receptors and guanylyl cyclase c receptor. These therapies are administered via the oral route.
The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 15.7%, and the average probability a drug advances from Phase III is 63.9%. Drugs, on average, take 10.0 years from Phase I to approval, compared to 9.8 years in the overall gastroenterology (non inflammatory bowel disease) space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for OIC have been in the late phases of development, with 60% of trials in Phase III–IV, and 40% in Phase I–II.
Clinical trial activity in the OIC space is dominated by completed trials. Progenics Pharmaceuticals has the highest number of completed clinical trials for OIC, with 13 trials.
Progenics Pharmaceuticals leads the industry sponsors with the highest overall number of clinical trials for OIC, followed by Pfizer.

OVERVIEWKEY TAKEAWAYSDISEASE BACKGROUND

TREATMENT

Management of OIC with laxatives
Management of OIC with opioid antagonists
Management of OIC with Amitiza, a secretagogue chloride channel activator

EPIDEMIOLOGY

OIC, recent prevalence studies
OIC, challenges

MARKETED DRUGSPIPELINE DRUGSPROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

RedHill Obtains Israel Rights To Movantik From AstraZeneca
Yuhan, Processa Ink Deal On Gastrointestinal Disease Pipeline
RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status
Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

LIST OF FIGURES

Figure 1: Overview of pipeline drugs for OIC in the US
Figure 2: Pipeline drugs for OIC, by company
Figure 3: Pipeline drugs for OIC, by drug type
Figure 4: Pipeline drugs for OIC, by classification
Figure 5: Probability of success in the gastroenterology (non inflammatory bowel disease)-other pipeline
Figure 6: Clinical trials in OIC
Figure 7: Top 10 drugs for clinical trials in OIC
Figure 8: Top 10 companies for clinical trials in OIC
Figure 9: OIC trials sponsors by status
Figure 10: OIC trials sponsors, by phase

LIST OF TABLES

Table 1: Marketed drugs for OIC
Table 2: Pipeline drugs for OIC in the US
Table 3: Historical global sales, by drug ($m), 2015–19
Table 4: Forecasted global sales, by drug ($m), 2021–25

Table of Contents

Related Topics

Related Reports

Global Opioid Induced Constipation Market Report and Forecast 2024-2032

Constipation Treatment: Global Strategic Business Report

Constipation Treatment Global Market Report 2024

Opioid-Induced Constipation - Pipeline Insight, 2024

Constipation Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type